ZYNRELEF® (HTX-011): A Comprehensive Pharmacological and Clinical Review of a Novel Dual-Acting, Extended-Release Local Anesthetic for Postoperative Pain Management

Executive Summary

ZYNRELEF® (bupivacaine and meloxicam extended-release solution), formerly known as HTX-011, represents a first-in-class, non-opioid, dual-acting local anesthetic (DALA) developed by Heron Therapeutics.[1] It is engineered to provide sustained postsurgical analgesia for up to 72 hours, directly addressing a critical period of acute postoperative pain.[1] The formulation's innovation lies in its synergistic mechanism, which combines the potent local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam.[4] This combination is encapsulated within a proprietary Biochronomer® polymer technology, a tri(ethylene glycol) poly(orthoester)-based system that facilitates a controlled, extended release of both active ingredients directly at the surgical site.[4] The inclusion of meloxicam is not merely additive but mechanistically essential; it counteracts surgery-induced local inflammation and subsequent tissue acidosis, a physiological state that otherwise limits the efficacy of bupivacaine. By normalizing the local pH, meloxicam potentiates the penetration of bupivacaine into nerve cells, thereby maintaining its analgesic effect for the full 72-hour duration.[6]

The efficacy and safety of ZYNRELEF were rigorously established in a comprehensive clinical development program, most notably the pivotal Phase III EPOCH 1 (bunionectomy) and EPOCH 2 (inguinal herniorrhaphy) studies.[10] In these randomized, double-blind, placebo- and active-controlled trials, ZYNRELEF demonstrated statistically significant superiority over both saline placebo and the standard-of-care, bupivacaine hydrochloride (HCl) solution, across all primary and key secondary endpoints. These endpoints included reduction in mean pain intensity over 72 hours, reduction in total opioid consumption, and an increased proportion of patients who remained entirely opioid-free.[1] These findings position ZYNRELEF as the first and only extended-release local anesthetic to prove superiority over bupivacaine solution in Phase III trials.[1]

Following a challenging regulatory pathway that included two Complete Response Letters related to non-clinical and manufacturing issues, ZYNRELEF received U.S. Food and Drug Administration (FDA) approval in May 2021.[14] Its indication has since been expanded to encompass a broad range of soft tissue and orthopedic surgical procedures.[17] With its proven ability to provide sustained, non-opioid analgesia and significantly reduce or eliminate the need for postoperative opioids, ZYNRELEF is positioned as a foundational component of modern multimodal, opioid-sparing pain management strategies.[1]

Introduction: The Unmet Need in Postoperative Pain Management

The management of acute postoperative pain remains a significant clinical challenge with profound implications for patient recovery, healthcare costs, and public health.[15] The period immediately following surgery, particularly the first 72 hours, is characterized by the most intense pain, which, if inadequately controlled, can lead to patient dissatisfaction, delayed mobilization, prolonged hospital stays, and an increased risk of developing chronic postsurgical pain.[3]

For decades, the cornerstone of postoperative pain management has been systemic opioid analgesics.[20] While effective, opioids are associated with a well-documented and burdensome side effect profile, including nausea, vomiting, constipation, sedation, and respiratory depression, all of which can impede recovery.[11] More critically, the widespread use of opioids in the perioperative setting is a major contributor to the ongoing opioid crisis. Approximately 50 million Americans undergo surgery annually, and a significant percentage of these patients receive opioid prescriptions, creating a substantial risk for new persistent opioid use, misuse, and diversion.[1]

In response, clinical practice has shifted toward multimodal analgesia (MMA), a strategy that combines different analgesic agents and techniques to achieve synergistic pain relief while minimizing opioid-related adverse events.[19] Local anesthetics are a key component of MMA, offering the advantage of targeted, non-systemic pain blockade. Bupivacaine HCl, an amide-type local anesthetic, is the most widely used agent in this class; however, its utility is constrained by a limited duration of action, typically providing effective analgesia for 12 hours or less.[2] This duration is insufficient to cover the entire period of severe postoperative pain, often necessitating the subsequent use of opioids. While extended-release formulations like liposomal bupivacaine have been developed, demonstrating superiority over standard bupivacaine HCl has remained an elusive goal.[22] This therapeutic gap highlights a clear and urgent unmet need for a long-acting, reliable, and safe non-opioid analgesic that can provide sustained pain relief throughout the critical first 72 hours post-surgery, thereby reducing or eliminating the need for opioids.[15] HTX-011 was specifically designed and developed to fill this void.

Formulation and Synergistic Mechanism of Action

The therapeutic innovation of ZYNRELEF is rooted in its unique formulation, which combines two well-characterized active ingredients within a sophisticated drug delivery system to produce a synergistic analgesic effect that overcomes the physiological barriers of the postoperative environment.

A. Component Analysis: Bupivacaine and Meloxicam

ZYNRELEF is a fixed-dose combination of two active pharmaceutical ingredients: bupivacaine and meloxicam.[5]

• Bupivacaine: A potent, long-acting local anesthetic of the amide class, bupivacaine has been a mainstay of regional anesthesia and analgesia for decades.[6] Its mechanism of action involves the reversible blockade of voltage-gated sodium ion channels on the intracellular side of the nerve cell membrane. This blockade prevents the influx of sodium ions necessary for depolarization, thereby inhibiting the initiation and propagation of nerve impulses, or pain signals, from the site of injury to the central nervous system.[6]
• Meloxicam: A nonsteroidal anti-inflammatory drug (NSAID) belonging to the oxicam family, meloxicam exhibits potent anti-inflammatory, analgesic, and antipyretic properties.[6] It was specifically selected for the ZYNRELEF formulation due to its potent anti-inflammatory activity and long half-life, which aligns with the desired 72-hour duration of action.[8]

The two agents are combined in a fixed ratio of 33 parts bupivacaine to one part meloxicam by weight, a concentration determined to be optimal for achieving the desired synergistic effect.[4] For example, the highest-strength vial contains 400 mg of bupivacaine and 12 mg of meloxicam.[8]

B. The Biochronomer® Delivery System: Engineering a 72-Hour Release Profile

The extended duration of action of ZYNRELEF is enabled by Heron Therapeutics' proprietary Biochronomer® drug delivery technology.[6] This system is a tri(ethylene glycol) poly(orthoester)-based polymer engineered specifically for controlled drug release.[4] The polymer formulation is a viscous, hydrophilic solution with unique physical properties. Upon application into the surgical site, contact with moisture in the surrounding tissues causes the solution to become even more viscous, allowing it to adhere to the tissue and remain in place without migrating.[6]

The active ingredients, bupivacaine and meloxicam, are released from the polymer matrix via a process of controlled diffusion over a period of approximately 72 hours.[6] Following the release of the drugs, the polymer itself undergoes hydrolysis, breaking down into small, benign, water-soluble fragments that are primarily eliminated from the body via the kidneys.[6] This advanced delivery system is the vehicle that allows for sustained therapeutic concentrations of both drugs directly at the site of tissue injury.

C. The Dual-Acting Synergistic Effect: A Mechanistic Breakthrough

The core innovation of ZYNRELEF is not simply the co-delivery of two drugs, but the creation of a synergistic effect that solves a fundamental physiological problem in postoperative pain management. The efficacy of traditional local anesthetics is known to be compromised in the environment of a surgical wound. Surgical trauma invariably triggers an inflammatory cascade, which leads to the accumulation of acidic byproducts and a localized drop in tissue pH, a state known as acidosis.[6]

This acidic environment presents a significant barrier to the action of bupivacaine. Local anesthetics are weak bases that exist in equilibrium between an un-ionized (lipid-soluble) form and an ionized (water-soluble) form. Only the un-ionized form can penetrate the lipid-rich nerve cell membrane to reach the intracellular sodium channels.[6] In the acidic environment of an inflamed surgical site, the equilibrium shifts, causing a greater proportion of bupivacaine molecules to become ionized

outside the nerve cell. These charged molecules are unable to cross the cell membrane, effectively trapping the anesthetic and preventing it from reaching its target. This phenomenon explains why the analgesic effect of standard bupivacaine often wanes long before the drug has been cleared from the surgical site.[3]

ZYNRELEF was engineered to directly overcome this challenge. The low dose of meloxicam released from the Biochronomer® polymer exerts a potent local anti-inflammatory effect. By inhibiting the inflammatory process at the surgical site, meloxicam mitigates the drop in tissue pH, effectively normalizing the local environment.[4] This pH normalization shifts the equilibrium back in favor of the un-ionized, lipid-soluble form of bupivacaine. As a result, a significantly greater number of bupivacaine molecules are able to penetrate the nerve cell membrane, where they then become ionized and can effectively block the sodium channels to provide sustained pain relief.[6]

This synergistic mechanism has been validated in both preclinical and clinical studies. Preclinical research in a validated postoperative pig model demonstrated that HTX-011 application resulted in a less acidic tissue pH at the surgical site compared to controls.[3] Crucially, a Phase II clinical study in bunionectomy patients directly compared HTX-011 to the same Biochronomer® polymer formulation containing either bupivacaine alone or meloxicam alone. The results showed that HTX-011 provided a reduction in pain intensity that was substantially greater than that of bupivacaine alone, meloxicam alone, or even the calculated sum of the two individual components, providing definitive clinical evidence of a true synergistic effect.[2] This mechanistic advance is what enables ZYNRELEF to maintain its analgesic efficacy over the full 72-hour release period.

D. Pharmacokinetics: Predictable Release and Systemic Exposure

The pharmacokinetic profile of ZYNRELEF is characterized by controlled release, delayed peak plasma concentrations, and a wide safety margin against systemic toxicity.

• In Vitro Release Rates: The release of the active ingredients from the Biochronomer® polymer is predictable and sustained. Validated in vitro release assays at 37°C show that approximately 52% of bupivacaine and 44% of meloxicam are released within the first 24 hours. By 48 hours, 81% of both drugs have been released, and by 72 hours, over 93% of bupivacaine and 95% of meloxicam have been delivered.[7]
• In Vivo Plasma Concentrations: As expected for an extended-release product, systemic absorption is gradual. This results in a significantly delayed time to maximum plasma concentration () and a prolonged, low-level plateau in the plasma concentration-time profile when compared to the sharp peak observed after an injection of immediate-release bupivacaine HCl.[7]
• Safety Margin: This controlled absorption translates directly into a superior safety profile with respect to Local Anesthetic Systemic Toxicity (LAST), a rare but potentially fatal complication of high plasma concentrations of local anesthetics. The plasma concentration threshold for bupivacaine-related central nervous system toxicity is generally considered to be approximately 2000 ng/mL.[7] Clinical studies involving the highest approved dose of ZYNRELEF (400 mg bupivacaine/12 mg meloxicam) demonstrated mean maximum plasma concentrations ( ) of approximately 672 to 710 ng/mL. These levels are several-fold lower than the established toxic threshold, providing a substantial margin of safety.[7]
• Predictability: A key advantage of the ZYNRELEF formulation is the consistency of its absorption profile. The absorption of immediate-release bupivacaine HCl can be highly variable and is heavily influenced by the vascularity of the surgical site, leading to unpredictable peak plasma concentrations. In contrast, the dose-normalized  for bupivacaine released from ZYNRELEF is consistent and predictable across different surgical procedures with varying degrees of vascularity.[7] This predictability allows clinicians to administer a high therapeutic dose of local anesthetic with a significantly lower and more reliable risk of systemic toxicity, representing a critical improvement in the risk-benefit profile.

Pivotal Phase III Clinical Trial Evidence: The EPOCH Studies

The clinical efficacy of ZYNRELEF was established in a robust development program, anchored by two pivotal Phase III studies, EPOCH 1 and EPOCH 2. A defining feature of these trials was their rigorous design, which included not only a placebo control but also an active comparator arm using the current standard-of-care, bupivacaine HCl solution. This design set a high bar for success, as demonstrating superiority over an established active therapy is a significant achievement in clinical research.[1]

A. EPOCH 1 Study: Bunionectomy

The EPOCH 1 study (NCT03015532) was a randomized, double-blind, multicenter trial that evaluated ZYNRELEF in patients undergoing primary unilateral first metatarsal bunionectomy, an orthopedic procedure known for producing moderate to severe postoperative pain.[10]

• Study Design: A total of 412 subjects were randomized to receive a single intraoperative dose of one of three treatments: ZYNRELEF (60 mg bupivacaine/1.8 mg meloxicam), saline placebo, or immediate-release bupivacaine HCl (50 mg).[10]
• Endpoints: The primary efficacy endpoint was the mean area under the curve (AUC) of the Numeric Rating Scale (NRS) for pain intensity scores through 72 hours () for ZYNRELEF compared with saline placebo. There were four key secondary endpoints hierarchically tested for statistical significance: (1) mean  for ZYNRELEF versus bupivacaine HCl; (2) mean total postoperative opioid consumption through 72 hours for ZYNRELEF versus saline placebo; (3) mean total postoperative opioid consumption through 72 hours for ZYNRELEF versus bupivacaine HCl; and (4) the proportion of subjects who were opioid-free through 72 hours for ZYNRELEF versus bupivacaine HCl.[5]
• Efficacy Results: ZYNRELEF successfully met the primary endpoint and all four key secondary endpoints. The results demonstrated a statistically significant and clinically meaningful benefit over both placebo and the active comparator. The sustained effect was also notable; among the ZYNRELEF-treated patients who were opioid-free through 72 hours, 82% remained opioid-free through Day 28, suggesting that effective early pain control can have a lasting impact on opioid use.[12]

Endpoint	HTX-011 (60 mg/1.8 mg)	Bupivacaine HCl (50 mg)	Saline Placebo	P-value (vs. Comparator)
Mean Pain Intensity Score ()	323.3	393.5	445.3	vs. Placebo  vs. Bupivacaine HCl
Mean Total Opioid Consumption (mg morphine equiv.) through 72 hours	10.3	13.8	16.4	vs. Placebo  vs. Bupivacaine HCl
Proportion of Opioid-Free Subjects through 72 hours	29%	11%	2%	vs. Placebo  vs. Bupivacaine HCl
Table 1: Summary of Key Efficacy Results from the EPOCH 1 Phase III Trial (Bunionectomy) 5

B. EPOCH 2 Study: Inguinal Herniorrhaphy

The EPOCH 2 study (NCT03237481) was a similarly designed Phase III trial that assessed ZYNRELEF in patients undergoing unilateral open inguinal herniorrhaphy, a common soft tissue surgical procedure.[13]

• Study Design: The trial randomized 418 subjects to receive a single intraoperative dose of either ZYNRELEF (300 mg bupivacaine/9 mg meloxicam), saline placebo, or immediate-release bupivacaine HCl (75 mg).[11]
• Endpoints: The endpoint structure mirrored that of the EPOCH 1 study, with the primary endpoint being the mean  of pain intensity scores versus placebo, followed by the same key secondary endpoints comparing ZYNRELEF to both placebo and bupivacaine HCl for pain reduction and opioid use.[11]
• Efficacy Results: As in the EPOCH 1 study, ZYNRELEF met all primary and key secondary endpoints, demonstrating superiority over both control groups. The durability of the opioid-sparing effect was again observed, with over 84% of patients who were opioid-free at 72 hours remaining so through Day 28.[13]

Endpoint	HTX-011 (300 mg/9 mg)	Bupivacaine HCl (75 mg)	Saline Placebo	P-value (vs. Comparator)
Mean Pain Intensity Score ()	269	342	351	vs. Placebo  vs. Bupivacaine HCl
Mean Total Opioid Consumption (mg morphine equiv.) through 72 hours	6.9	9.2	11.1	vs. Placebo  vs. Bupivacaine HCl
Proportion of Opioid-Free Subjects through 72 hours	51%	40%	22%	vs. Placebo  vs. Bupivacaine HCl
Table 2: Summary of Key Efficacy Results from the EPOCH 2 Phase III Trial (Herniorrhaphy) 11

The consistency of these positive results across two very different surgical models—a bony orthopedic procedure (bunionectomy) and a soft tissue procedure (herniorrhaphy)—is a powerful validation of the drug's broad applicability. The underlying mechanism of action, which involves counteracting the universal physiological response of inflammation-induced acidosis, appears to be fundamentally effective regardless of the specific tissue type involved. This robustness suggests ZYNRELEF is a versatile therapeutic tool rather than a niche product, a conclusion later supported by its expanded FDA indications.[18]

Furthermore, the clinical trial data points to an effect beyond simple opioid reduction, revealing the potential for opioid elimination in a significant proportion of surgical patients. While reducing total opioid consumption is a primary goal of MMA, enabling a patient to avoid opioids altogether is a more profound clinical achievement. The statistically significant increase in the percentage of opioid-free patients (e.g., from 40% with standard care to 51% with ZYNRELEF in the herniorrhaphy study) is clinically meaningful.[13] The long-term follow-up data, showing that the majority of these patients remained opioid-free for a month, suggests that effectively controlling acute pain in the immediate postoperative period with a powerful, long-acting non-opioid like ZYNRELEF may interrupt the cascade that can lead to prolonged opioid use, thereby directly addressing a key pathway of the opioid crisis.[12]

C. Supporting Evidence and Follow-On Studies

The evidence base for ZYNRELEF extends beyond the two pivotal trials. Efficacy has also been demonstrated in other surgical models, including total knee arthroplasty (TKA), further supporting its broad utility.[4] In addition, a series of single-arm, open-label follow-on studies (EPOCH 1 and 2 Follow-On, EPOCH TKA Follow-On) were conducted. In these studies, ZYNRELEF was administered as the foundational analgesic within a scheduled, non-opioid MMA regimen that also included oral over-the-counter analgesics. The results showed that this combined approach led to even lower mean pain scores, which remained in the mild range for the full 72-hour period, and further increased the number of patients who required no opioids post-surgery.[23]

Comprehensive Safety and Tolerability Profile

The safety of ZYNRELEF has been evaluated in 14 clinical studies encompassing a total of 1,627 patients across various surgical procedures.[35] The overall safety profile was found to be generally comparable to that of saline placebo and bupivacaine HCl solution in controlled trials.[10]

A. Boxed Warning: Cardiovascular and Gastrointestinal Risks

As ZYNRELEF contains the NSAID meloxicam, its label includes the standard FDA-mandated boxed warning for this class of drugs.[1] The warning highlights two major risks:

• Serious Cardiovascular Thrombotic Events: NSAIDs can cause an increased risk of serious and potentially fatal cardiovascular events, including myocardial infarction and stroke. This risk may increase with the duration of use. Consequently, ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.[1]
• Serious Gastrointestinal (GI) Bleeding, Ulceration, and Perforation: NSAIDs increase the risk of serious GI adverse events, which can also be fatal. These events can occur at any time without warning symptoms. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at a greater risk.[1]

B. Contraindications and Key Precautions

In addition to the boxed warning, ZYNRELEF is contraindicated in patients with:

• Known hypersensitivity to any amide local anesthetic, NSAIDs, aspirin, or other components of the formulation.[1]
• A history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.[1]
• The medication is also contraindicated for use in obstetrical paracervical block anesthesia.[1]

Key warnings and precautions advise clinicians to monitor for dose-related local anesthetic toxicity, as the toxic effects of local anesthetics are additive; additional local anesthetics should be avoided for 96 hours following ZYNRELEF administration.[27] Other precautions relate to the potential for hepatotoxicity, NSAID-induced hypertension, heart failure and edema, and renal toxicity.[18] A critical precaution highlighted in the labeling is the

risk of chondrolysis with unapproved intra-articular use. Animal studies demonstrated that direct intra-articular administration of ZYNRELEF into the knee joint resulted in cartilage necrosis and degeneration; therefore, direct exposure to articular cartilage should be limited.[28]

C. Analysis of Adverse Events from Clinical Trials

In the controlled clinical trials, the most common adverse reactions (incidence 5%) reported with ZYNRELEF were vomiting in soft tissue procedures, and constipation and headache in orthopedic procedures.[1] The overall incidence of treatment-emergent adverse events was similar across the ZYNRELEF, bupivacaine HCl, and placebo groups.[10]

A notable finding from the safety analysis is that patients treated with ZYNRELEF experienced a lower overall incidence of opioid-related adverse events (such as nausea, vomiting, constipation, and dizziness) compared to patients in both the saline placebo and bupivacaine HCl groups.[6] This observation is a direct and logical consequence of the significantly reduced opioid consumption in the ZYNRELEF arm.

The safety profile of ZYNRELEF thus presents a clinical trade-off. Its use introduces the class-specific systemic risks of an NSAID, as reflected in the boxed warning. However, this must be weighed against its demonstrated ability to mitigate two other significant sources of risk in the postoperative setting. First, by substantially reducing or eliminating the need for opioids, it lowers the incidence of common and debilitating opioid-related side effects that can delay recovery. Second, as established by its pharmacokinetic profile, its extended-release formulation provides a significant safety margin against the potentially catastrophic risk of LAST when compared to an equivalent bolus dose of standard bupivacaine HCl. The clinical decision to use ZYNRELEF involves accepting the known, manageable risks of a low-dose, short-term NSAID in exchange for reducing the immediate, highly prevalent risks of opioids and the rare but severe risk of systemic local anesthetic toxicity.

D. Drug Interactions and Special Populations

Clinically significant drug interactions are primarily related to the meloxicam component. Concomitant use with other drugs that interfere with hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs) may increase the risk of bleeding and requires careful monitoring.[27] NSAIDs can also reduce the efficacy of certain antihypertensive medications, such as ACE inhibitors, ARBs, and diuretics, necessitating blood pressure monitoring.[27] Use in elderly patients requires caution due to a greater risk of GI events, and use in late pregnancy is not recommended due to risks to the fetus.[27]

Approved Indications, Dosing, and Administration

A. FDA-Approved Indications and Limitations of Use

ZYNRELEF was first approved by the U.S. FDA on May 12, 2021, for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.[17]

The indication has since undergone significant expansion, reflecting the drug's broad utility. In December 2021, the approval was expanded to include foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.[17] A further expansion occurred on January 23, 2024, broadening the indication to more generally cover soft tissue and orthopedic surgical procedures, including foot and ankle procedures and others where direct exposure to articular cartilage is avoided.[17]

A key limitation of use is noted in the prescribing information: safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic procedures, large (4 or more level) spinal surgeries, and head and neck procedures.[18]

B. Dosing and Available Strengths

ZYNRELEF is intended for single-dose administration only.[27] It is available in several single-dose glass vial strengths, including 400 mg bupivacaine/12 mg meloxicam and 200 mg bupivacaine/6 mg meloxicam.[8] The maximum recommended dose for any procedure is 400 mg of bupivacaine and 12 mg of meloxicam, which corresponds to a volume of 14 mL.[36] The specific volume and dose are selected based on the size of the surgical wound and the procedure being performed.

Surgical Procedure Example	Recommended Max Volume	Corresponding Dose (Bupivacaine mg / Meloxicam mg)
Bunionectomy	2.3 mL	60 mg / 1.8 mg
1- to 3-level Spinal Surgery	7 mL	200 mg / 6 mg
Open Inguinal Herniorrhaphy	10.5 mL	300 mg / 9 mg
Total Knee Arthroplasty	14 mL	400 mg / 12 mg
Abdominoplasty	14 mL	400 mg / 12 mg
Cesarean Section	14 mL	400 mg / 12 mg
Table 3: Dosing and Administration Guidelines for ZYNRELEF 4
Note: This table provides examples for guidance. The total dose should be based on the size of the surgical wound, not to exceed the maximum dose of 400 mg/12 mg.

C. Preparation and Intraoperative Administration Technique

ZYNRELEF is administered via a unique and specific technique. It is supplied as a kit containing all necessary sterile components: a single-dose glass vial, Luer lock syringe(s), a vented vial spike or vial access needle, and Luer lock cone-shaped applicator(s).[27] Only the components provided in the kit should be used for preparation and administration.[27]

The administration is performed intraoperatively by the surgeon. After final irrigation and suctioning of the surgical wound, but prior to suturing of the tissue layers, ZYNRELEF is applied directly into the surgical site.[4] The application is performed

without a needle using the provided cone-shaped applicator.[6] The viscous solution is instilled to cover the wound surfaces. This needle-free technique is an important safety feature, as it eliminates the risk of accidental needle-stick injuries to healthcare professionals and minimizes the risk of inadvertent intravascular injection.[6]

Regulatory and Developmental History

The journey of ZYNRELEF from an investigational agent (HTX-011) to an approved therapy was marked by both significant recognition of its innovative potential and considerable regulatory challenges, ultimately leading to divergent commercial outcomes in the United States and Europe.

A. The U.S. FDA Pathway: A Story of Persistence

The potential of HTX-011 to address a significant unmet need in postoperative pain was recognized early by the U.S. FDA. The agency granted the drug several expedited program designations: Fast Track designation in the fourth quarter of 2017, Breakthrough Therapy designation in the second quarter of 2018, and Priority Review designation upon its initial New Drug Application (NDA) submission in December 2018.[14] These designations underscored the strength of the clinical data and the drug's potential to provide a substantial improvement over available therapies.

Despite this early promise, the path to approval was not straightforward. Heron Therapeutics received a Complete Response Letter (CRL) from the FDA in April 2019, followed by a second CRL in June 2020 after resubmission.[14] It is crucial to analyze the nature of these setbacks. The FDA did not raise any issues related to the clinical efficacy or safety data from the extensive Phase III program. Instead, the CRLs cited the need for additional non-clinical information and deficiencies related to Chemistry, Manufacturing, and Controls (CMC).[12] After diligently addressing these issues, Heron resubmitted the NDA in November 2020, which finally culminated in FDA approval on May 13, 2021.[1]

B. The European Medicines Agency (EMA) Trajectory: Approval Without Launch

In parallel, ZYNRELEF pursued regulatory approval in Europe. In March 2019, the European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) for review under its Centralised Procedure. This pathway was granted on the basis that HTX-011 constituted a "significant scientific innovation".[16] The review process proceeded smoothly, with the EMA's Committee for Medicinal Products for Human Use (CHMP) adopting a positive opinion in July 2020, recommending the drug for approval.[39] This led to the European Commission granting a marketing authorization valid throughout the European Union in September 2020.[18]

However, in a surprising strategic move, Heron Therapeutics announced in 2023 that it had cancelled the marketing authorizations for ZYNRELEF in both the United Kingdom and the European Union, stating that the company did not plan to commercially launch the product in those regions.[18]

This divergence between achieving full regulatory approval in two major global markets but only pursuing commercialization in one highlights a critical reality of the pharmaceutical industry. Clinical superiority and successful navigation of the regulatory process do not automatically guarantee global market access. The decision to withdraw from the European market, despite having a fully approved and clinically superior product, was likely driven by a complex interplay of economic and strategic factors. These could include unfavorable pricing and reimbursement negotiations with national health systems, logistical challenges of a European launch, and a corporate decision to concentrate financial and marketing resources on the larger and potentially more lucrative U.S. market. This outcome serves as a powerful case study demonstrating that a drug's ultimate availability to patients is governed by a confluence of scientific, regulatory, and commercial forces.

Therapeutic Positioning and Clinical Integration

A. ZYNRELEF in the Multimodal Analgesia Paradigm

ZYNRELEF is not positioned as a standalone panacea for postoperative pain but rather as a foundational component within a comprehensive, multimodal analgesia (MMA) strategy.[19] The core principle of MMA is to use a combination of analgesic drugs and techniques with different mechanisms of action to achieve synergistic pain relief while minimizing the doses and side effects of any single agent, particularly opioids.[21]

By providing a consistent, powerful baseline of non-opioid local analgesia for the first 72 hours post-surgery, ZYNRELEF effectively covers the period of most intense pain. This allows for the layering of other non-opioid agents, such as scheduled oral acetaminophen or other systemic NSAIDs, to manage any breakthrough pain.[23] This integrated approach optimizes pain control and has been shown in follow-on clinical studies to further reduce, and in many cases eliminate, the need for rescue opioids.[23]

B. Comparative Analysis: Advantages and Disadvantages

A comparative analysis of ZYNRELEF against other common postoperative pain management options clarifies its unique therapeutic position.

• Versus Systemic Opioids: The primary advantage of ZYNRELEF is the avoidance of the significant systemic side effects associated with opioids, including sedation, respiratory depression, nausea, vomiting, constipation, and the potential for abuse and addiction.[1] Clinical trials confirmed that ZYNRELEF use leads to a lower incidence of opioid-related adverse events.[35] The main disadvantage is that its effect is localized to the surgical site and it cannot treat pain from other sources.
• Versus Systemic NSAIDs: ZYNRELEF's advantage lies in its targeted delivery. It provides a potent anti-inflammatory effect directly at the site of tissue injury, which is mechanistically crucial for its synergistic action with bupivacaine.[6] This localized action may reduce the systemic exposure and side effects compared to oral or IV NSAIDs. The disadvantage is that the absorbed meloxicam still carries the systemic class risks outlined in the boxed warning.[1]
• Versus Standard Local Anesthetics (e.g., Bupivacaine HCl): ZYNRELEF demonstrates multiple, clear advantages. Its duration of action is vastly superior (72 hours vs. 12 hours).[2] It is the only extended-release local anesthetic to have proven superiority over bupivacaine HCl in Phase III trials for both pain control and opioid reduction.[1] Its pharmacokinetic profile is more predictable and carries a lower risk of LAST for a given therapeutic dose, and its needle-free application improves safety for healthcare personnel.[7] The primary disadvantage is a higher acquisition cost compared to generic bupivacaine HCl.[8]
• Versus Other Extended-Release Local Anesthetics (e.g., Liposomal Bupivacaine): ZYNRELEF's key distinguishing feature is its unique, synergistic mechanism of action designed to overcome local acidosis, a key physiological factor that can limit the efficacy of other extended-release formulations.[9] Its demonstrated superiority over the bupivacaine HCl standard-of-care in Phase III trials is a differentiating factor in its evidence base.[1]

C. Conclusion: A Paradigm Shift in Local Anesthetic Therapy

ZYNRELEF (HTX-011) represents a significant and intelligent evolution in the field of postoperative pain management. It moves beyond simple extended-release technology to offer a mechanistically elegant solution to a long-standing physiological problem—the attenuation of local anesthetic efficacy by surgical site acidosis. By synergistically combining the well-established anesthetic bupivacaine with the anti-inflammatory agent meloxicam within a sophisticated polymer delivery system, ZYNRELEF maintains potent, localized analgesia for the critical 72-hour postoperative period.

Its value is substantiated by a robust body of high-quality clinical evidence from the EPOCH trials, which demonstrated unequivocal superiority over the current standard-of-care in reducing both pain intensity and the consumption of opioids. In doing so, ZYNRELEF not only improves the patient recovery experience by minimizing pain and opioid-related side effects but also provides a powerful tool in the broader public health effort to combat the opioid crisis. By enabling a significant portion of patients to avoid opioids altogether after surgery, it helps to close a key gateway to persistent opioid use. For these reasons, ZYNRELEF is appropriately positioned as a foundational, non-opioid cornerstone in modern multimodal analgesic regimens for a broad range of surgical procedures.

Works cited

1. Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours, accessed September 30, 2025, https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-us-fda-approval-zynreleftm-htx-011
2. Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain, accessed September 30, 2025, https://rapm.bmj.com/content/45/2/117
3. The HTX-011 Story - MD Biosciences, accessed September 30, 2025, https://www.mdbneuro.com/blog/htx-011-story
4. Full article: HTX-011 Effectively Reduces Postoperative Pain Intensity and Opioid use in the Elderly - Taylor & Francis Online, accessed September 30, 2025, https://www.tandfonline.com/doi/full/10.2217/pmt-2021-0043
5. HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in bunionectomy: phase III results from the randomized EPOCH 1 study, accessed September 30, 2025, https://rapm.bmj.com/content/44/7/700
6. Bupivacaine and meloxicam (HTX-011) for post- operative pain - NIHR Innovation Observatory, accessed September 30, 2025, https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/11640-Bupivacaine-in-addition-to-Meloxicam-for-Post-Operative-Pain-V1.1-OCT2019-NON-CONF.pdf
7. HTX-011: Predictable Release Rates of Bupivacaine and Meloxicam for 72 Hours - Heron Therapeutics, accessed September 30, 2025, https://www.herontx.com/wp-content/uploads/2020/11/ASA_2020_Max-Dose.pdf
8. FAQs - ZYNRELEF.com, accessed September 30, 2025, https://zynrelef.com/frequently-asked-questions/
9. A Foundation for Postoperative Pain Management | ZYNRELEF, accessed September 30, 2025, https://zynrelef.com/mechanism-of-action/
10. HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in bunionectomy: phase III results from the randomized EPOCH 1 study - PubMed, accessed September 30, 2025, https://pubmed.ncbi.nlm.nih.gov/31113830/
11. HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study - PubMed Central, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6938470/
12. Heron Therapeutics Announces Publication of Results from Phase 3 EPOCH 1 Study of HTX-011 in Patients Undergoing Bunionectomy, accessed September 30, 2025, https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-publication-results-phase-3-epoch-1
13. Heron Therapeutics Announces Publication of Results from EPOCH ..., accessed September 30, 2025, https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-announces-publication-results-epoch-2-phase-3
14. Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain, accessed September 30, 2025, https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-receives-complete-response-letter-htx-011-0
15. Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours - PR Newswire, accessed September 30, 2025, https://www.prnewswire.com/news-releases/heron-therapeutics-announces-us-fda-approval-of-zynrelef-htx-011-for-the-management-of-postoperative-pain-for-up-to-72-hours-301290467.html
16. Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain - PR Newswire, accessed September 30, 2025, https://www.prnewswire.com/news-releases/heron-therapeutics-announces-fda-extension-of-review-period-for-nda-for-htx-011-for-the-management-of-postoperative-pain-301007658.html
17. Zynrelef (bupivacaine and meloxicam) FDA Approval History - Drugs ..., accessed September 30, 2025, https://www.drugs.com/history/zynrelef.html
18. ZYNRELEF® - Heron Therapeutics, accessed September 30, 2025, https://www.herontx.com/product-portfolio/zynrelef/
19. A novel long-acting local anesthetic - HTX-011 (ZYNRELEF™) for postoperative pain control, accessed September 30, 2025, https://pubmed.ncbi.nlm.nih.gov/36199229/
20. Pain medicines after surgery - Mayo Clinic, accessed September 30, 2025, https://www.mayoclinic.org/pain-medications/art-20046452
21. The Management of Postoperative Pain - U.S. Pharmacist, accessed September 30, 2025, https://www.uspharmacist.com/article/the-management-of-postoperative-pain
22. Efficacy of New Long-Acting Bupivacaine HTX-011 in Providing Pain Relief for Patients Undergoing Elective Surgery – A Meta-analysis of Prospective Randomized Controlled Trials - PMC - PubMed Central, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7819416/
23. Select efficacy results from HTX-011 phase III studies, EPOCH-1... - ResearchGate, accessed September 30, 2025, https://www.researchgate.net/figure/Select-efficacy-results-from-HTX-011-phase-III-studies-EPOCH-1-bunionectomy-and_tbl1_341847327
24. (PDF) HTX-011, a Proprietary, Extended-Release Synergistic Combination of Bupivacaine and Meloxicam for the Relief of Acute Postoperative Pain - ResearchGate, accessed September 30, 2025, https://www.researchgate.net/publication/316252350_HTX-011_a_Proprietary_Extended-Release_Synergistic_Combination_of_Bupivacaine_and_Meloxicam_for_the_Relief_of_Acute_Postoperative_Pain
25. HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial - PubMed, accessed September 30, 2025, https://pubmed.ncbi.nlm.nih.gov/32561266/
26. APPLICATION NUMBER: - 211988Orig1s000 SUMMARY REVIEW - accessdata.fda.gov, accessed September 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/211988Orig1s000SumR.pdf
27. zynrelef - fda - accessdata.fda.gov, accessed September 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211988s000lbl.pdf
28. ZYNRELEF | Synergy and PK/PD, accessed September 30, 2025, https://zynrelef.com/synergy/
29. Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain, accessed September 30, 2025, https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-publication-mechanism-action-data
30. Zynrelef TM Heron Therapeutics - Anesthesia Patient Safety Foundation, accessed September 30, 2025, https://www.apsf.org/article/zynrelef-heron-therapeutics/
31. 72 Hours of Postoperative Pain Relief | ZYNRELEF, accessed September 30, 2025, https://zynrelef.com/efficacy-pain-reduction/
32. Opioid Reduction and Elimination - ZYNRELEF.com, accessed September 30, 2025, https://zynrelef.com/efficacy-opioid-reduction/
33. NCT03237481 | Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2), accessed September 30, 2025, https://clinicaltrials.gov/study/NCT03237481
34. 211988Orig1s013 | FDA, accessed September 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/211988Orig1s013.pdf
35. Safety - ZYNRELEF.com, accessed September 30, 2025, https://zynrelef.com/safety/
36. Zynrelef Prescribing Information - ZYNRELEF.com, accessed September 30, 2025, https://www.zynrelef.com/prescribing-information.pdf
37. ZYNRELEF® Generic or Proper Name: bupivacaine and meloxicam Sponsor: Heron Therapeutics, Inc. Approval Date: 12/08/2021 Indication, accessed September 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/211988Orig1s005.pdf
38. Heron Announces European Medicines Agency Validation of ..., accessed September 30, 2025, https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-announces-european-medicines-agency-validation-marketing
39. Heron Therapeutics Receives European Commission Authorization for ZYNRELEF™ (HTX-011) for the Treatment of Postoperative Pain, accessed September 30, 2025, https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-receives-european-commission-authorization
40. CHMP Backs Bupivacaine/Meloxicam (Zynrelef) for Postop Pain - Medscape, accessed September 30, 2025, https://www.medscape.com/viewarticle/934564
41. Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain - BioSpace, accessed September 30, 2025, https://www.biospace.com/heron-therapeutics-receives-positive-chmp-opinion-for-zynrelef-htx-011-for-the-management-of-postoperative-pain
42. Zynrelef | European Medicines Agency (EMA) - Europa.eu, accessed September 30, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/zynrelef